Medicinal Products

Dáil Éireann Debate, Tuesday - 14 July 2026

• Debates
• Find a debate
  • Dáil debates
  • Seanad debates
  • Committee debates
• Find a vote
  • Dáil votes
  • Seanad votes
  • Committee votes
• Parliamentary questions
  • Written questions
  • Oral questions
• Search tips
• Utterances having an adverse effect

Tuesday, 14 July 2026

Questions (748)

Claire Kerrane

Question:

748. Deputy Claire Kerrane asked the Minister for Health the reason a drug (details supplied) is not accessible in Ireland to cancer patients despite approval by the European Medicines Agency and its accessibility in many other parts of the EU and in the North of Ireland, if she will examine this and make the drug available for cancer patients where their oncology team has recommended it; and if she will make a statement on the matter. [52886/26]

Written answers

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• Previous Answer
• Next Answer